Screener
Neuropace, Inc. NPCE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
| (in thousands, except for share and per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liability | 2,256 | 2,117 |
| Deferred revenue | 123 | 141 |
| Current liabilities of discontinued operations | — | 596 |
| Total current liabilities | 17,433 | 17,814 |
| Long-term debt | 59,014 | 58,884 |
| Operating lease liability, net of current portion | 8,661 | 9,836 |
| Total liabilities | 85,108 | 86,534 |
| Commitments and contingencies (Note 5) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Neuropace, Inc.'s total current liabilities?
- Neuropace, Inc. (NPCE) reported total current liabilities of $17.43M in Q2 2026.
- How has Neuropace, Inc.'s total current liabilities changed year-over-year?
- Neuropace, Inc.'s total current liabilities increased by 1.7% year-over-year, from $17.14M to $17.43M.
- What is the long-term trend for Neuropace, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Neuropace, Inc.'s total current liabilities has grown at a 13.2% compound annual growth rate (CAGR), from $9.6M to $17.81M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Neuropace, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude